BACKGROUND: Metabolic syndrome (MetS) has been linked with an increased risk of developing cancer; however, the association between MetS and cancer mortality remains less clear. Little research has focused on pre-cancer risk factors that may affect the outcome of treatment. The purpose of this study was to examine the association between MetS and all-cancer mortality in men. METHODS: The participants included 33,230 men aged 20-88 years who were enrolled in the Aerobics Centre Longitudinal Study and who were free of known cancer at the baseline. RESULTS: At baseline 28% of all the participants had MetS. During an average of 14 years follow-up, there were a total of 685 deaths due to cancer. MetS at baseline was associated with a 56% greater age-adjusted risk in cancer mortality. CONCLUSION: These data show that MetS is associated with an increased risk of all-cause cancer mortality in men. Based on these findings, it is evident that successful interventions should be identified to attenuate the negative effects of MetS.
BACKGROUND:Metabolic syndrome (MetS) has been linked with an increased risk of developing cancer; however, the association between MetS and cancer mortality remains less clear. Little research has focused on pre-cancer risk factors that may affect the outcome of treatment. The purpose of this study was to examine the association between MetS and all-cancer mortality in men. METHODS: The participants included 33,230 men aged 20-88 years who were enrolled in the Aerobics Centre Longitudinal Study and who were free of known cancer at the baseline. RESULTS: At baseline 28% of all the participants had MetS. During an average of 14 years follow-up, there were a total of 685 deaths due to cancer. MetS at baseline was associated with a 56% greater age-adjusted risk in cancer mortality. CONCLUSION: These data show that MetS is associated with an increased risk of all-cause cancer mortality in men. Based on these findings, it is evident that successful interventions should be identified to attenuate the negative effects of MetS.
Authors: Petra H Lahmann; Kurt Hoffmann; Naomi Allen; Carla H van Gils; Kay-Tee Khaw; Bertrand Tehard; Franco Berrino; Anne Tjønneland; Janne Bigaard; Anja Olsen; Kim Overvad; Françoise Clavel-Chapelon; Gabriele Nagel; Heiner Boeing; Dimitrios Trichopoulos; George Economou; George Bellos; Domenico Palli; Rosario Tumino; Salvatore Panico; Carlotta Sacerdote; Vittorio Krogh; Petra H M Peeters; H Bas Bueno-de-Mesquita; Eiliv Lund; Eva Ardanaz; Pilar Amiano; Guillem Pera; José R Quirós; Carmen Martínez; María J Tormo; Elisabet Wirfält; Göran Berglund; Göran Hallmans; Timothy J Key; Gillian Reeves; Sheila Bingham; Teresa Norat; Carine Biessy; Rudolf Kaaks; Elio Riboli Journal: Int J Cancer Date: 2004-09-20 Impact factor: 7.396
Authors: Lorenzo Scappaticcio; Maria Ida Maiorino; Giuseppe Bellastella; Dario Giugliano; Katherine Esposito Journal: Endocrine Date: 2016-12-31 Impact factor: 3.633
Authors: Wambui G Gathirua-Mwangi; Patrick O Monahan; Mwangi J Murage; Jianjun Zhang Journal: Cancer Causes Control Date: 2017-01-17 Impact factor: 2.506
Authors: Elizabeth M Cespedes Feliciano; Candyce H Kroenke; Jeffrey A Meyerhardt; Carla M Prado; Patrick T Bradshaw; Andrew J Dannenberg; Marilyn L Kwan; Jingjie Xiao; Charles Quesenberry; Erin K Weltzien; Adrienne L Castillo; Bette J Caan Journal: J Clin Oncol Date: 2016-10-20 Impact factor: 44.544
Authors: Jason R Jaggers; Vivek K Prasad; Wesley D Dudgeon; Steven N Blair; Xuemei Sui; Stephanie Burgess; Gregory A Hand Journal: AIDS Care Date: 2014-05-27
Authors: Geoffrey C Kabat; Mimi Y Kim; Ulrike Peters; Marcia Stefanick; Lifang Hou; Jean Wactawski-Wende; Catherine Messina; James M Shikany; Thomas E Rohan Journal: Eur J Cancer Prev Date: 2012-07 Impact factor: 2.497
Authors: Kumaraswamy Naidu Chitrala; Dena G Hernandez; Michael A Nalls; Nicolle A Mode; Alan B Zonderman; Ngozi Ezike; Michele K Evans Journal: Epigenetics Date: 2019-12-04 Impact factor: 4.528
Authors: K Esposito; P Chiodini; A Capuano; G Bellastella; M I Maiorino; E Parretta; A Lenzi; D Giugliano Journal: J Endocrinol Invest Date: 2013-02 Impact factor: 4.256